In the NHL setting, CD19 expression data post-CAR T cell therapy are limited due to the need for tissue biopsy at the time of relapse and use of lower sensitivity methods of detection (i.e., immunohistochemistry, IHC) compared to flow cytometry (FC) that is typically used in B cell ALL [21]. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.